Prothena (PRTA) Set to Announce Quarterly Earnings on Tuesday

Prothena (NASDAQ:PRTA) will announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($1.18) per share for the quarter.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $1.22 earnings per share for the quarter, beating the consensus estimate of ($1.01) by $2.23. The company had revenue of $132.01 million during the quarter, compared to analysts’ expectations of $10.73 million. Prothena had a negative return on equity of 9.00% and a negative net margin of 23.44%. The firm’s quarterly revenue was up 3184.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.03) earnings per share. On average, analysts expect Prothena to post $-2 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Prothena Stock Performance

Shares of PRTA opened at $17.70 on Friday. The stock has a market capitalization of $951.91 million, a price-to-earnings ratio of -17.70 and a beta of 0.16. Prothena has a 52-week low of $15.30 and a 52-week high of $41.54. The stock’s 50-day simple moving average is $18.65 and its 200 day simple moving average is $20.48.

Analyst Upgrades and Downgrades

PRTA has been the subject of a number of analyst reports. Royal Bank of Canada cut their price objective on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research report on Monday, September 30th. StockNews.com upgraded Prothena from a “sell” rating to a “hold” rating in a research report on Monday, August 12th. Bank of America reduced their target price on Prothena from $33.00 to $31.00 and set a “neutral” rating for the company in a research report on Tuesday, October 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $84.00 price target on shares of Prothena in a report on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Prothena currently has a consensus rating of “Moderate Buy” and an average price target of $61.86.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.